免疫联合抗血管生成治疗晚期NSCLC的疗效及预后标志物
该研究在真实世界中纳入天津医科大学肿瘤医院140例经倾向评分匹配的晚期NSCLC患者,比较单免与免疫联合抗血管生成治疗,发现联合组中位PFS延长2.3个月、OS无显著差异;LDH、LIPI、FOXP3+ T细胞与疗效预后相关。
要点
- 免疫联合抗血管生成较单免延长晚期NSCLC二/三线中位PFS 2.3个月,OS无差异。
- 低LDH≤230.5 U/L且LIPI=0患者从联合治疗中PFS及OS获益更显著。
- LDH与LIPI可作为无创可动态监测的标志物用于筛选联合治疗优势人群。
核心结论
- 免疫联合抗血管生成治疗可延长晚期经治NSCLC患者PFS,但OS无显著获益。
- LDH和LIPI有望成为筛选联合治疗优势人群及判断预后的无创、可动态监测生物标志物。
研究设计与样本
- 真实世界回顾性研究,收集2019年1月至2023年1月天津医科大学肿瘤医院晚期NSCLC患者临床病理资料。
- 比较单免疫治疗组与免疫联合抗血管生成治疗组,并进行倾向评分匹配(PSM)。
- PSM后共纳入140例NSCLC患者。
主要发现
- 联合组中位PFS为6.9个月,较单药组4.6个月延长2.3个月(P=0.003)。
- 两组中位OS分别为21.3和20.9个月,差异无统计学意义(P=0.628)。
- 低LDH≤230.5 U/L患者中联合治疗延长PFS(7.9 vs. 12.8个月,P<0.001)及OS(22.5 vs. 34.0个月,P=0.013)。
- LIPI=0患者中联合治疗延长PFS(8.6 vs. 13.6个月,P=0.005)及OS(22.5 vs. 30.9个月,P=0.018)。
- 多因素分析显示TNM分期(HR=2.067,95% CI:1.322~3.232,P=0.001)、ECOG评分(HR=3.785,95% CI:2.307~6.211,P<0.001)和LIPI(HR=2.737,95% CI:1.618~4.630,P<0.001)是PFS独立预测因素。
关键数值与推荐
- 联合组中LDH和LIPI与PFS及OS均相关(均P<0.05)。
- PD-L1表达在单药组和联合组中均与OS相关(均P<0.05)。
- FOXP3+ T细胞计数>90个/高倍视野患者PFS更短(2.7 vs. 8.4个月,P=0.031),OS有缩短趋势(18.7 vs. 25.8个月,P=0.080)。
临床怎么用
- 对晚期经治NSCLC患者,免疫联合抗血管生成可作为二/三线治疗选择以延长PFS。
- 治疗前及治疗中可检测LDH和LIPI,低LDH≤230.5 U/L且LIPI=0者优先考虑联合治疗。
- 肿瘤微环境FOXP3+ T细胞计数可能辅助判断预后,高计数者PFS较短。
局限性
- 单中心真实世界回顾性研究,样本量有限,结论需前瞻性验证。
- OS无显著差异,联合治疗总生存获益尚不明确。
- FOXP3+ T细胞与OS仅呈缩短趋势(P=0.080),证据强度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the potential efficacy of immune checkpoint inhibitors (ICIs) combined with anti-angiogenic therapy as second- or third-line treatment for advanced non-small cell lung cancer (NSCLC) in a real-world setting, and to identify predictive and prognostic biomarkers. Methods: We collected clinicopathological data of patients with advanced NSCLC who received either immunotherapy alone (monotherapy group) or immunotherapy combined with anti-angiogenic therapy (combination group) at Tianjin Medical University Cancer Institute & Hospital between January 2019 and January 2023, and performed propensity score matching (PSM). Survival analysis was conducted using multivariate Cox regression analysis. Multiplex immunofluorescence staining was employed to explore the relationships among short-term efficacy, prognosis, and the tumor microenvironment. Results: After PSM, a total of 140 NSCLC patients were included. The median progression-free survival (mPFS) in the combination group was 6.9 months, which was 2.3 months longer than that in the monotherapy group (4.6 months, P=0.003). There was no significant difference in overall survival (OS) between the two groups (21.3 vs. 20.9 months, P=0.973). In patients with low lactate dehydrogenase (LDH) ≤230.5 U/L and a lung immune prognosis index (LIPI) of 0, combination therapy significantly prolonged the PFS (7.9 vs. 12.8 months, P<0.001; 8.6 vs. 13.6 months, P=0.005) and OS (22.5 vs. 34.0 months, P=0.013; 22.5 vs. 30.9 months, P=0.018). PD-L1 expression was correlated with OS in both the monotherapy and combination groups (both P<0.05). Multivariate analysis identified clinical stage (HR=2.067, 95% CI: 1.322, 3.232, P=0.001), Eastern Cooperative Oncology Group (ECOG) performance status score (HR=3.785, 95% CI: 2.307, 6.211, P<0.001), and LIPI (HR=2.737, 95% CI: 1.618, 4.630, P<0.001) as independent predictors of PFS. In the combination group, LDH and LIPI were both associated with PFS and OS (all P<0.05). Multiple immunofluorescence staining confirmed that patients with a FOXP3+ T-cell count > 90 per high-power field had shorter PFS (2.7 vs. 8.4 months, P=0.031) and a trend toward shorter OS (18.7 vs. 25.8 months, P=0.080). Conclusions: Immunotherapy combined with anti-angiogenic therapy can prolong PFS. LDH and LIPI are expected to serve as non-invasive, dynamically monitorable biomarkers for identifying the population most likely to benefit from combination therapy and for predicting short-term efficacy and prognosis. 目的: 探索真实世界中免疫检查点抑制剂联合抗血管生成治疗作为晚期经治非小细胞肺癌(NSCLC)二三线治疗的潜在疗效,并探索疗效预测和预后的生物标志物。 方法: 收集2019年1月至2023年1月间天津医科大学肿瘤医院接受单免疫治疗(单药组)或免疫联合抗血管生成治疗(联合组)的晚期NSCLC患者的临床病理资料,并进行倾向评分匹配(PSM)。生存分析采用Kaplan-Meier法,影响因素分析采用多因素Cox回归分析,采用多重免疫荧光染色技术分析近期疗效、预后与肿瘤微环境之间的关系。 结果: PSM后,共纳入140例NSCLC患者。联合组的中位无进展生存时间(PFS,6.9个月)较单药组延长2.3个月(4.6个月,P=0.003)。两组间总生存时间(OS)差异无统计学意义(单药组和联合组中位OS分别为21.3和20.9个月,P=0.628)。在低乳酸脱氢酶(LDH)≤230.5 U/L及肺免疫预后指数(LIPI)=0的患者中,联合治疗可以显著延长患者的PFS(中位PFS 7.9和12.8个月,P<0.001;8.6和13.6个月,P=0.005)及OS(中位OS 22.5和34.0个月,P=0.013;22.5和30.9个月,P=0.018)。单药组和联合组患者中,程序性死亡受体配体1表达均与OS有关(均P<0.05)。多因素分析结果显示,TNM分期(HR=2.067,95% CI:1.322~3.232,P=0.001)、美国东部肿瘤协作组体能状态评分(HR=3.785,95% CI:2.307~6.211,P<0.001)和LIPI(HR=2.737,95% CI:1.618~4.630,P<0.001)是PFS的独立预测因素。联合组中,LDH和LIPI与PFS及OS均相关(均P<0.05)。多重免疫荧光染色证实,FOXP3+ T细胞计数>90个/高倍视野的患者PFS更短(中位PFS 2.7和8.4个月,P=0.031),并且OS也有缩短趋势(中位OS 18.7和25.8个月,P=0.080)。 结论: 免疫联合抗血管生成治疗可延长PFS,LDH和LIPI有望成为筛选联合治疗优势人群并判断近期疗效及预后且无创、可动态监测的生物标志物。.
引用
- Zhang CC, Zhang XR, Wei XY, et al. [Efficacy of immunotherapy combined with anti-angiogenesis therapy in patients with advanced NSCLC and identification of prognostic biomarkers]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42927951. doi:10.3760/cma.j.cn112152-20250821-00412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。